Suheung Co (008490) Fair Value & Analysis
Healthcare · KR · Market cap 232B KRW
Fair value as of: Aug 13, 2026
From 24 valuation models · updated today
Share price +37.9% over the past month.
A solid business, screening 143% undervalued on our models.
What matters now
- The price is below even our cautious bear case (38,805 KRW). The market is more pessimistic than our downside scenario.
- Solid quality (53/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range (38,805 KRW to 82,985 KRW) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range 11,483 KRW – 54,679 KRW · fair‑value band 38,805 KRW – 82,985 KRW · the 27,300 KRW price screens below the 66,388 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Suheung Co (008490) currently trades at 27,300 KRW, while our model-based Fair Value estimate is 66,388 KRW, implying the stock looks roughly 143.2% undervalued today. The Quality Score stands at 53/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Suheung Co generated revenue of 743B KRW at a net margin of 6.7%. Revenue grew 11.5% year over year. It earns a return on equity of 10.4%. Net debt stands at 385B KRW. Fundamentals as of Aug 13, 2026
Our scenario range runs from 38,805 KRW (bear case) to 82,985 KRW (bull case); at 27,300 KRW, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 14% below its 52-week high and 58% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 143%, 008490 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Growth Earnings (70,546 KRW) versus Asset-Based (29,401 KRW). Highest evidence: Growth DCF (80).
Notify me when 008490 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 51 · Market factors (momentum, volatility) 61
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Suheung Co., Ltd. engages in produces and sells hard and soft capsules. The company provides solid dosage forms, including hard and soft capsule, tablets, powder, granules; fluidity and concentrated liquids; gummy, sticky and water jellies.
Full company description
Suheung Co., Ltd. engages in produces and sells hard and soft capsules. The company provides solid dosage forms, including hard and soft capsule, tablets, powder, granules; fluidity and concentrated liquids; gummy, sticky and water jellies. It offers medical supplies, such as prescription medicines; over-the-counter drugs comprising antipyretic-analgesics, cold medicine, digestive medicine, liver-treatment medicine, and nutritional supplements; and quasi-drugs, which includes low-content vitamin-cosmetic products, multi-vitamin, toothpaste, effervescent tablet, and chewable tablet. In addition, it provides its capsules under Embocaps brand name. The company was founded in 1973 and is headquartered in Cheongju-si, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Suheung Co reported revenue of 722B KRW in FY2025 versus 597B KRW in FY2021, a compound +4.9%/yr. Reported net income was 43.5B KRW in FY2025, compounding −5.1%/yr from FY2021.
Watch 008490: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 624 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | -52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹8,500 | ₹1,932 | -77% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,915 | ₹1,163 | -76% |
| PharmaEssentia Corporation 6446 | 1,440 TWD | 233.93 TWD | -84% |
| Cipla Limited CIPLA | ₹1,463 | ₹1,001 | -32% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,167 | ₹703.32 | -40% |
| Lupin Limited LUPIN | ₹2,281 | ₹2,477 | +9% |
| Mankind Pharma Limited MANKIND | ₹2,433 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,200 | ₹874.79 | -27% |
Compare Suheung Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Suheung Co (008490) overvalued or undervalued?
What is the fair value of 008490?
What is the quality score of 008490?
What is the revenue of Suheung Co (008490)?
What is the net profit margin of 008490?
Does Suheung Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Suheung Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.